Sponsor

Baker Heart and Diabetes Institute

Clinical research sponsor

Published trials28
Recruiting shown4
Roles2
SourceClinicalTrials.gov

Clinical trials

28 shown
Risk-guided Disease Management Plan to Prevent Heart Failure in Patients Treated With Previous Chemotherapy (REDEEM)NCT04962711 · lead sponsor · 2023-03-30
RECRUITING
Use of Artificial Intelligence-Guided Echocardiography to assIst cardiovascuLar Patient managEmentNCT05558605 · lead sponsor · 2023-02-24
RECRUITING
Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE)NCT04983823 · lead sponsor · 2021-11-18
RECRUITING
Exercise to Improve Neurovascular Function in Breast Cancer SurvivorsNCT06925529 · lead sponsor · 2025-11-03
NOT_YET_RECRUITING
Reducing Cognitive Impairment by Management of Heart Failure as a Modifiable Risk FactorNCT06088212 · lead sponsor · 2024-07-01
UNKNOWN
Sham Controlled Clinical Trial of Renal Denervation in Patients With Resistant HypertensionNCT02444442 · lead sponsor · 2015-06-01
COMPLETED
Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD)NCT01483053 · lead sponsor · 2014-01-01
UNKNOWN
Renal Denervation to Improve Outcomes in Patients With End-stage Renal DiseaseNCT02021019 · lead sponsor · 2014-01-01
COMPLETED
Renal Denervation for Uncontrolled HypertensionNCT02016573 · lead sponsor · 2013-12-01
WITHDRAWN
Alleviating the Metabolic Side Effects of Antipsychotic MedicationsNCT01567124 · lead sponsor · 2012-05-01
WITHDRAWN
Major Depressive Disorder - Understanding The Link Between The Brain And The HeartNCT01568307 · lead sponsor · 2012-05-01
COMPLETED
Renal Denervation for Complicated HypertensionNCT01865253 · lead sponsor · 2012-05-01
TERMINATED
Renal Denervation for Resistant HypertensionNCT01865240 · lead sponsor · 2012-02-01
TERMINATED
The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and HypertensionNCT01360710 · lead sponsor · 2012-01-01
UNKNOWN
Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney DiseaseNCT01094769 · lead sponsor · 2011-04-01
COMPLETED
Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With ObesityNCT01180231 · lead sponsor · 2010-09-01
UNKNOWN
Effect of Ghrelin on Sympathetic Nervous SystemNCT00912587 · lead sponsor · 2009-06-01
COMPLETED
Study of High Dosage of Losartan in Comparison to Low Dose of Losartan in Heart Failure PatientsNCT02238457 · lead sponsor
WITHDRAWN
The STOP-MED CTRCD TrialNCT06183437 · collaborator · 2024-03-04
RECRUITING
Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using DapagliflozinNCT07225465 · collaborator · 2026-02-01
NOT_YET_RECRUITING
Promote Health With Digital Tools Among Adults With Type 2 Diabetes/Prediabetes and/or HypertensionNCT05648383 · collaborator · 2022-10-01
COMPLETED
The Effects of Reducing Prolonged Sitting Bouts in Individuals at High Risk of or With Type 2 DiabetesNCT03482596 · collaborator · 2018-02-21
COMPLETED
Frequent Activity Snacks BreaksNCT03083587 · collaborator · 2017-02-01
COMPLETED
The Effects of RVX000222 on Glucose Metabolism in Individuals With Pre-diabetesNCT01728467 · collaborator · 2012-11-01
COMPLETED
Enhancement of Brown Adipose Tissue Function Via Chronic Pharmacological TreatmentNCT02236962 · collaborator · 2012-04-01
UNKNOWN
Valsartan Intensified Primary Care Reduction of Blood Pressure StudyNCT00902304 · collaborator · 2009-07-01
COMPLETED
GLYCOSA Study:Effect of PAP Treatment on Glycemic Control in Patients With Type 2 DiabetesNCT00509223 · collaborator · 2007-07-01
COMPLETED
The Mauritius and Rodrigues Non-Communicable Disease (NCD) StudyNCT07048717 · collaborator · 1987-04-05
ACTIVE_NOT_RECRUITING

Sponsor roles

lead sponsor18
collaborator10

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.